Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

21 Aug 2013

Combination of anti-nausea drug and turmeric spice target cancer cells

In a laboratory, preclinical study recently published by the journal Organic & Biomolecular Chemistry, Virginia Commonwealth University Massey Cancer Center researchers combined structural features from anti-nausea drug thalidomide with common kitchen spice turmeric to create hybrid molecules that effectively kill multiple myeloma cells.

20 Aug 2013

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes.

13 Aug 2013

Celgene's pomalidomide gets approval in UK for multiple myeloma

Celgene confirmed today that Pomalidomide Celgene▼ (pomalidomide), a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland.

9 Aug 2013

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.

8 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Ethicor Pharma Ltd. for the manufacture and distribution of the oral formulation of lasofoxifene in the European Economic Area, Switzerland and the Indian Subcontinent.

24 Jul 2013

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

Ligand Pharmaceuticals Incorporated announces the signing of a global license agreement with Azure Biotech for the development of a novel formulation of lasofoxifene targeting an underserved market in women's health.

22 Jul 2013

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called -myc,- paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

20 Jul 2013

UCSF researchers find way to knock down cancers caused by myc protein

UC San Francisco researchers have found a way to knock down cancers caused by a tumor-driving protein called "myc," paving the way for patients with myc-driven cancers to enroll in clinical trials for experimental treatments.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Pharmacyclics, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

10 Jul 2013

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen Biotech, Inc. and Johnson & Johnson Innovation announced today the establishment of a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease and the discovery of next generation therapeutic solutions.

27 Jun 2013

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

MorphoSys AG and Celgene Corporation today announced an agreement to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

27 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Combination of anti-nausea drug and turmeric spice target cancer cells

Preclinical study reveals pomalidomide shows promising results for treatment of CNS lymphoma

Celgene's pomalidomide gets approval in UK for multiple myeloma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

ImmunoGen reports net loss of $21.9 million in Q4 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Ligand Pharmaceuticals, Ethicor Pharma sign license agreement for lasofoxifene

Ligand, Azure Biotech sign global license agreement for development of lasofoxifene

UCSF researchers find a way to knock down cancers caused by tumor-driving protein

UCSF researchers find way to knock down cancers caused by myc protein

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Pharmacyclics submits ibrutinib NDA to FDA for two B-cell malignancies

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

MorphoSys, Celgene agree to jointly develop MOR202 for patients with multiple myeloma

Eisai submits BELVIQ NDS with Health Canada

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in